



Please join us for the Inaugural Seminar in the Rutgers University-Industry Cancer Seminar Series

Oncology Pipeline Update

Jim Cassidy, MD, PhD

Vice President, Oncology Clinical and Translational Research Bristol-Myers Squibb

Howard L. Kaufman, MD, FACS

Chief Surgical Officer and
Associate Director for Clinical Sciences, Rutgers Cancer Institute of
New Jersey and Professor of
Surgery, Rutgers Robert Wood Johnson Medical School

Edmund C. Lattime, PhD

Associate Director for Education and Training, Cancer Institute of New Jersey and Professor of Surgery, Robert Wood Johnson Medical School

Janice Mehnert, MD

Interim Director, Phase I and Developmental Therapeutics, Cancer Institute of New Jersey and Associate Professor of Medicine, Robert Wood Johnson Medical School

Derek Sant' Angelo, PhD

Division Chief, Developmental Biology Associate Professor of Pediatrics, Robert Wood Johnson Medical School

September 30, 2014

4:00-6:00 PM

Followed by a light reception

Rutgers Cancer Institute of New Jersey 195 Little Albany Street, New Brunswick, NJ 08903 Auditorium A & B

SEMINAR GOALS

The series is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners. This seminar will provide an update on drugs in the developmental pipeline at BMS and current basic and clinical research projects at Rutgers, with the objective of initiating a dialogue for validating novel cancer therapeutics.

